Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel

Serena Pillozzi, Massimo D'Amico, Giulia Petroni, Marinella Veltroni, MD, Claudio Favre, MD, Andrea Becchetti, Giuseppe Basso, Annarosa Arcangeli, MD PhD

Blood (2016) 128 (22): 3953.

https://doi.org/10.1182/blood.V128.22.3953.3953

Published: 2016

Journal Articles

Long-Term Safety Experience with Arsenic Trioxide in Patients with Acute Promyelocytic Leukemia

Martin S. Tallman, Francesco Lo-Coco, Ashutosh Pathak

Blood (2016) 128 (22): 4034.

https://doi.org/10.1182/blood.V128.22.4034.4034

Published: 2016

Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 375.

https://doi.org/10.1182/blood.V124.21.375.375

Published: 2014

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 48.

https://doi.org/10.1182/blood.V120.21.48.48

Published: 2012

Journal Articles

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Marika Masselli, Serena Pillozzi, Massimo D'Amico, Luca Gasparoli, Olivia Crociani, Matteo Stefanini, Kennet Mugridge, Wolfang Tiedke, Andrea Becchetti, Annarosa Arcangeli, MD, PhD

Blood (2012) 120 (21): 1506.

https://doi.org/10.1182/blood.V120.21.1506.1506

Published: 2012

Journal Articles

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Richard A. Larson, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Gianantonio Rosti, MD, Jose L. Lopez, MD, Leif Stenke, MD, PhD, Hirohisa Nakamae, M.D., Ph.D., Stuart L. Goldberg, M.D., Ming-Chung Wang, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Christine-Elke Ortmann, Timothy P. Hughes, MD, MBBS, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 2291.

https://doi.org/10.1182/blood.V116.21.2291.2291

Published: 2010

Journal Articles

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Gene A Wetzstein, PharmD, BCOP, Timothy J. George, PharmD, BCOP, Mahsa Sharifi, PharmD, Van D Hoang, PharmD, BCOP, Viet Q Ho, PharmD, BCOP, Rod E Quilitz, PharmD, BCOP, Dana A Spears, PharmD, BCOP, Rami S. Komrokji, MD, Alan F List, MD, Jeffrey E Lancet, MD, John N Greene, MD

Blood (2009) 114 (22): 2059.

https://doi.org/10.1182/blood.V114.22.2059.2059

Published: 2009

Journal Articles

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Harald A. Weber, MD, Feng Tai, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Jennifer Marlowe, Rong Lin, MD

Blood (2009) 114 (22): 3781.

https://doi.org/10.1182/blood.V114.22.3781.3781

Published: 2009

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Toni K. Choueiri, MD, Esteban Walker, PhD, Rachid C. Baz, MD, Rony M. Abou-Jawde, MD, Snehal G. Thakkar, MD, Bridget McGowan, Megan Kelly, Steven Andresen, MD, Mohamad Hussein, MD

Blood (2005) 106 (11): 5155.

https://doi.org/10.1182/blood.V106.11.5155.5155

Published: 2005

Journal Articles

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Dilip Unnikrishnan, Janice P. Dutcher, Nikita Varshneya, Richard Lucariello, Marietta Api, Susan Garl, Peter H. Wiernik, Salvatore Chiaramida

Blood (2001) 97 (5): 1514–1516.

https://doi.org/10.1182/blood.V97.5.1514

Published: 2001

NARROW

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel

Long-Term Safety Experience with Arsenic Trioxide in Patients with Acute Promyelocytic Leukemia

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only